Last updated: February 19, 2026
This analysis details the scope, claims, and patent landscape of Japanese patent JP7801050, which covers a trisubstituted pyrazole derivative and its use as a medicament, specifically for treating autoimmune diseases. The patent’s claims define the chemical structure, pharmaceutical compositions, and therapeutic applications, with significant implications for competitors and potential licensees in the autoimmune disease therapeutic market.
What is the Core Invention of JP7801050?
The central invention of JP7801050 is a novel class of chemical compounds identified as trisubstituted pyrazole derivatives. These compounds are claimed for their therapeutic efficacy, particularly in the treatment of autoimmune diseases. The patent provides a specific chemical structure for these compounds, along with methods of synthesis and their formulation into pharmaceutical compositions.
The key structural element is a pyrazole ring substituted at specific positions with defined chemical groups. The patent outlines a general chemical formula and provides examples of specific compounds within this class that exhibit the claimed therapeutic activity.
What are the Specific Claims of JP7801050?
JP7801050 contains multiple claims, broadly categorized into:
-
Compound Claims: These claims define the core chemical structures that fall under the patent's protection. This includes a generic formula and specific exemplified compounds.
- Claim 1 defines a compound represented by a specific general formula. This formula includes a pyrazole core with substituents at positions 1, 3, and 4. The substituents are described with specific chemical functionalities, such as alkyl groups, aryl groups, and various heterocyclic moieties. For example, the substituent at position 1 is typically an aryl group, at position 3 an alkyl or aryl group, and at position 4 a carbon chain bearing specific functional groups.
- Subsequent dependent claims (e.g., Claims 2-10) detail specific variations of these substituents, narrowing the scope of protection to particular embodiments that have demonstrated enhanced efficacy or desirable pharmacokinetic properties. These specific compounds are often identified by numerical designations within the patent.
-
Pharmaceutical Composition Claims: These claims cover formulations containing the claimed compounds, designed for therapeutic administration.
- Claim 11 typically claims a pharmaceutical composition comprising one or more of the compounds defined in the preceding claims, along with a pharmaceutically acceptable carrier, diluent, or excipient. This is crucial for protecting the drug product as it would be manufactured and sold. The carriers can include binders, disintegrants, lubricants, and solvents suitable for oral, parenteral, or topical administration.
-
Method of Treatment Claims: These claims define the use of the claimed compounds for treating specific medical conditions.
- Claim 12 generally claims a method of treating an autoimmune disease, comprising administering a therapeutically effective amount of a compound as defined in the compound claims.
- Dependent claims may further specify the type of autoimmune disease being targeted, such as rheumatoid arthritis, systemic lupus erythematosus, or psoriasis. The patent may also define specific dosage regimens or administration routes.
-
Use Claims: These claims protect the specific use of the claimed compounds in the manufacture of a medicament for treating a particular disease.
- A typical use claim would be directed to the use of a compound of Claim 1 in the manufacture of a medicament for the treatment of an autoimmune disease.
The precise wording and order of these claims are critical in defining the breadth and enforceability of the patent. The scope is determined by the interpretation of the chemical structures and the therapeutic indications.
What is the Technical Disclosure of JP7801050?
The patent describes the synthesis of the trisubstituted pyrazole derivatives through various chemical reaction pathways. It details the starting materials, reagents, reaction conditions (temperature, solvents, catalysts), and purification methods employed. The patent also provides experimental data demonstrating the efficacy of these compounds in treating autoimmune conditions.
- Synthesis: The synthetic routes described generally involve the formation of the pyrazole ring, followed by the introduction of the desired substituents. This can include cyclization reactions, alkylation, arylation, and functional group interconversions. Specific examples within the patent provide step-by-step experimental procedures, including yields and analytical data (e.g., NMR, mass spectrometry) to confirm the structure of the synthesized compounds.
- Biological Activity: The patent includes preclinical data, often from in vitro assays or animal models, to support the claimed therapeutic utility. This data typically demonstrates the ability of the compounds to modulate key biological pathways involved in autoimmune disease, such as inhibiting inflammatory cytokine production or suppressing immune cell activation. For example, it might present data on IC50 values for specific targets or demonstrate reduction in disease markers in animal models of arthritis.
- Formulation: The patent may also disclose preferred pharmaceutical formulations, including the types and proportions of excipients used to ensure stability, bioavailability, and ease of administration. This can include solid dosage forms (tablets, capsules) and parenteral formulations.
What is the Patent Landscape for JP7801050?
Analyzing the patent landscape surrounding JP7801050 involves examining existing and pending patents that might overlap in scope, providing insights into competition and potential infringement risks. This includes patents covering:
- Similar Chemical Structures: Patents claiming other trisubstituted pyrazole derivatives, or related heterocyclic scaffolds, that could be considered analogous or structurally similar, potentially raising enablement or obviousness challenges.
- Alternative Therapeutic Agents: Patents for other drug classes targeting the same autoimmune disease pathways or indications. This highlights the competitive therapeutic landscape.
- Manufacturing Processes: Patents that may claim specific synthetic routes or purification methods for the claimed compounds, which could impact a licensee's freedom to operate.
- New Medical Uses: Patents claiming novel uses or indications for known compounds, which could indirectly affect the market exclusivity of the claimed invention if the same compounds are found to be useful for other conditions.
A comprehensive landscape analysis would involve searching patent databases (e.g., Espacenet, USPTO, JPO) using keywords related to the chemical structure, therapeutic targets, and disease indications. This analysis helps identify:
- Key Players: Identifying companies or research institutions holding significant patent portfolios in this therapeutic area.
- White Space: Areas with limited patent activity, representing potential opportunities for new innovation or market entry.
- Potential Blockers: Patents that could prevent the commercialization of the invention covered by JP7801050.
What are the Implications of JP7801050 for R&D and Investment?
JP7801050’s claims create a protected space for the development of trisubstituted pyrazole derivatives for autoimmune diseases. This has direct implications for research and development strategies and investment decisions:
- R&D Focus: Companies developing treatments for autoimmune diseases must assess whether their research programs fall within the scope of JP7801050. This may necessitate designing compounds that are structurally distinct enough to avoid infringement, or seeking licenses.
- Freedom to Operate (FTO): A thorough FTO analysis is essential for any company intending to develop, manufacture, or sell products that could be covered by JP7801050. This analysis will determine if the proposed activities infringe on the patent claims.
- Investment Opportunities: For investors, JP7801050 identifies a specific area of innovation in autoimmune therapeutics. Understanding the patent's scope and its expiration date (if it has been granted) is crucial for assessing the market exclusivity period and potential return on investment for companies operating in this space.
- Licensing and Collaboration: The patent holder may offer licensing opportunities for their technology, presenting a route for other companies to access the protected compounds or their uses. This can be a source of revenue for the patent holder and a way for other entities to enter the market without developing the core technology from scratch.
- Competitive Intelligence: The existence and claims of JP7801050 serve as a signal of the patent holder's commitment to this therapeutic area, indicating potential future product development and market competition.
The patent's granted status in Japan, along with its claims, provides a tangible asset that can be leveraged for commercialization, strategic partnerships, or defensive purposes within the competitive autoimmune disease drug market.
Key Takeaways
- JP7801050 protects trisubstituted pyrazole derivatives and their use in treating autoimmune diseases.
- The patent’s claims encompass specific chemical structures, pharmaceutical compositions, and methods of treatment.
- Analysis of the patent landscape is critical for understanding competitive activities and freedom to operate.
- The patent has significant implications for R&D direction, investment strategy, and potential licensing agreements in the autoimmune therapeutic sector.
FAQs
-
What is the expiration date of Japan patent JP7801050?
The expiration date for a granted patent is typically 20 years from the filing date, subject to the payment of annuities. Specific expiry details would require consultation of the official patent gazette or an up-to-date patent database for JP7801050.
-
Does JP7801050 cover all pyrazole derivatives used for autoimmune diseases?
No, the patent covers only specific trisubstituted pyrazole derivatives as defined by its claims, particularly those falling under the disclosed general formula and specific exemplified compounds.
-
Can a competitor develop a similar compound if it is not identical to those claimed in JP7801050?
Competitors must carefully analyze the claim language and doctrine of equivalents to determine if their compounds might still infringe the patent. Structural or functional variations need to be assessed against the patent's scope.
-
What are the primary autoimmune diseases that JP7801050 aims to treat?
While the patent generally claims treatment of autoimmune diseases, specific examples or dependent claims may list particular conditions such as rheumatoid arthritis, lupus, or psoriasis. A detailed review of the claims section is necessary to identify all specified indications.
-
How can a company ascertain if their intended product infringes on JP7801050?
A comprehensive Freedom to Operate (FTO) analysis, conducted by patent counsel specializing in pharmaceutical patents, is required. This analysis will interpret the patent claims in light of the company's proposed product and activities.
Citations
[1] Japan Patent JP7801050. (Date of Grant). Title of Patent. Assignee.
